Sharps Technology, Inc. — Form 10-Q Summary
Entity note: The supplied filing is for Sharps Technology, Inc. (Nasdaq: STSS; warrants: STSSW), not Skyai, Inc. It covers the quarter and six months ended June 30, 2023; filed August 14, 2023. Financial statements are unaudited.
Business context and reporting period
Sharps is a pre-revenue medical-device company developing and seeking to commercialize patented safety syringes. It acquired the Safegard manufacturing facility in Hungary in July 2022. The company reports no revenue since inception and is building inventory to support potential orders.
Key financial metrics
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.53 million | $4.85 million |
| Net loss | $2.61 million | $4.72 million |
| Net loss per share, basic and diluted | $0.22 | $0.42 |
| Operating cash used | Not separately presented | $4.13 million |
| Investing cash used | Not separately presented | $0.34 million |
| Financing cash provided | Not separately presented | $3.24 million |
Gross margin is not meaningful because the company reported no revenue. At June 30, cash was $2.92 million, working capital was $1.20 million, total assets were $11.79 million, and total liabilities were $3.10 million. Current liabilities included a $1.51 million warrant liability. The company reported no outstanding note payable; its $2 million bridge note was repaid in 2022. Cash declined by $1.25 million during the first half.
Material changes versus comparable periods
- Second-quarter net results swung from $478,000 net income in 2022 to a $2.61 million net loss in 2023. The prior-year quarter included a $4.37 million gain from fair-value changes in warrants and contingent instruments; 2023 recorded a $90,000 loss.
- First-half net loss widened to $4.72 million from $1.39 million. The prior-year period included a $4.08 million fair-value gain; the 2023 period recorded a $94,000 fair-value loss.
- First-half operating expenses rose $725,000 to $4.85 million: R&D fell 48% to $558,000, while G&A rose 40% to $4.29 million. G&A included a $375,000 contract-settlement expense, higher payroll and stock compensation, and increased insurance and other costs.
- Operating cash use increased by $1.04 million year over year. February 2023 financing raised approximately $3.2 million net, but cash and working capital still declined from year-end.
- Inventory increased to $993,000 from $186,000 at year-end, including $680,000 of finished goods. Common shares outstanding increased to 11.66 million from 9.41 million, reflecting the February offering.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that working capital is not expected to fund planned operations for the next 12 months and that substantial doubt exists about the company’s ability to continue as a going concern. Continued operations depend on obtaining additional financing, which management expects to seek through equity or other financing.
- Commercialization: The company described a four-year collaboration framework with Nephron and an exclusive U.S. distribution agreement. The filing discusses planned product supply beginning in mid-2023, but reports no revenue through June 30, 2023. It provides no quantified revenue or earnings guidance.
- Potential dilution: At June 30, 11.43 million warrants and 2.36 million options were outstanding. The filing says 13.79 million options and warrants were excluded from diluted EPS as anti-dilutive. The February offering issued 2.25 million shares and warrants exercisable at $1.56 per share.
- Warrant accounting: Liability-classified warrants are remeasured each reporting date, with changes affecting reported income or loss. The warrant liability was $1.51 million at quarter-end.
- Subsequent employment settlement: After quarter-end, the company entered into a separation agreement with former executive and director Alan Blackman. It disclosed approximately $346,000 of severance and $29,000 of medical benefits, accrued at June 30; unvested options were fully vested. The agreement also provides for cancellation of his Series A preferred share after payments are completed.
- The company reported no material litigation, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements. Management said disclosure controls were effective and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the Nephron-related manufacturing and distribution plans have advanced to commercial shipments, and when revenue is expected to begin.
- Cash burn, remaining runway, and the amount and terms of any financing needed to continue operations.
- Whether inventory can be sold as planned, and any risk of obsolescence or additional manufacturing investment.
- The potential effect of outstanding warrants and options on dilution, including warrant exercises and fair-value volatility.
- The timing and full financial impact of the Blackman separation agreement and other contract-settlement costs.
- The MD&A states December 31, 2022 cash was $4.108 million, while the balance sheet reports $4.171 million; verify the correct comparative cash figure. The filing also contains differing fair-value table figures for warrant components, so confirm them against the XBRL or filed financial statements.